Anti-Human CEACAM5 (CD66e) (Labetuzumab) - 5 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

CEACAM5 is a member of the carcinoembryonic antigen-related cellular adhesion molecules(CEACAM) family1. In normal tissues, CEACAM5 functions as an adhesion molecule and hasroles in differentiation, immune modulation, and anoikis inhibition. Additionally, CEACAM5likely inhibits terminal differentiation and is also involved in activation of CD8+ suppressor Tcells. Dysregulation of CEACAM5 has been implicated in tumor initiation, progression, invasion, and metastasis1, 2 as well as in immune-related disease, particularly ulcerative colitis1.CEACAM5 is a clinical biomarker for colon cancer1 and is also a promising target of anti-cancerimmunotherapy2. CEACAM5 is a mediator of CEACAM1-induced apoptosis, and preventingthis interaction may prove beneficial to cancer treatment by blocking immune evasion by cancercells. hMN-14 (Labetuzumab; IMMU-130) is a CEACAM5 antibody-drug conjugate composed of ahumanized CEACAM5 monoclonal antibody conjugated via the hydrolysable linker CL2A to 7-ethyl-10-hydroxycamptothecin (SN-38), a potent topoisomerase I inhibitor3, 4. The antitumoractivity of labetuzumab has been tested for colorectal4, 7 and prostate cancers2. This non-therapeutic biosimilar is not a drug conjugate and thus does not contain the drug SN-38.

≥ 5.0 mg/ml

In normal tissues, CEACAM5 is expressed on gastric and intestinalmucous cells, particularly esophageal squamous epithelia, as well as in the pancreas. In cancers, CEACAM5 is expressed on the majority of solid tumors and is upregulated in a variety of humanepithelial malignancies (gastric, colorectal, pancreatic cancers) as well as in non-small cell lungcancer and melanoma. Tumors release CEACAM5 in a soluble form that can be used as abiomarker for cancer.